Limits...
Increased serum TRAIL and DR5 levels correlated with lung function and inflammation in stable COPD patients.

Wu Y, Shen Y, Zhang J, Wan C, Wang T, Xu D, Yang T, Wen F - Int J Chron Obstruct Pulmon Dis (2015)

Bottom Line: Several studies have suggested that tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its receptors were not only involved in diseases associated with apoptosis but also in inflammatory diseases.Serum levels of TRAIL, decoy receptor 5 (DR5), C-reactive protein, and tumor necrosis factor-α were analyzed using multiplex enzyme-linked immunosorbent assay kits.Mean levels of serum TRAIL and DR5 were significantly higher in COPD patients than those in controls (50.17±17.70 versus 42.09±15.49 pg/mL, P=0.029; 48.15±22.88 versus 38.94±10.95 pg/mL, P=0.032, respectively).

View Article: PubMed Central - PubMed

Affiliation: Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University, Chengdu, Sichuan, People's Republic of China ; Division of Pulmonary Diseases, State Key Laboratory of Biotherapy of China, Chengdu, Sichuan, People's Republic of China.

ABSTRACT

Background: Chronic obstructive pulmonary disease (COPD) is associated with abnormal systemic inflammation, and apoptosis is one of the pathogenic mechanisms of COPD. Several studies have suggested that tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its receptors were not only involved in diseases associated with apoptosis but also in inflammatory diseases. However, limited data about the possible relationship between COPD and TRAIL/TRAIL-receptors are available.

Objective: To evaluate the potential relationship between TRAIL/TRAIL-receptors and COPD.

Methods: Serum levels of TRAIL, decoy receptor 5 (DR5), C-reactive protein, and tumor necrosis factor-α were analyzed using multiplex enzyme-linked immunosorbent assay kits. Then, serum levels of TRAIL and DR5 in 57 COPD patients with 35 healthy controls were compared and correlated with lung function and systemic inflammation.

Results: Mean levels of serum TRAIL and DR5 were significantly higher in COPD patients than those in controls (50.17±17.70 versus 42.09±15.49 pg/mL, P=0.029; 48.15±22.88 versus 38.94±10.95 pg/mL, P=0.032, respectively). Serum levels of TRAIL and DR5 correlated inversely with forced expiratory volume in 1 second % predicted, an index of lung function in COPD (r=-0.354, P=0.007 for TRAIL; r=-0.394, P=0.002 for DR5) in all participants (r=-0.291, P=0.005 for TRAIL; r=-0.315, P=0.002 for DR5), while DR5 correlated positively with C-reactive protein (r=0.240, P=0.021 for total subjects) and TRAIL correlated positively with tumor necrosis factor-α (r=0.371, P=0.005 for COPD; r=0.349, P=0.001 for total subjects).

Conclusion: Our results suggested that circulating TRAIL and DR5 increased in COPD patients and were associated with lung function and systemic inflammation in COPD. Future studies are needed to verify whether and how TRAIL and its receptors play roles in COPD.

No MeSH data available.


Related in: MedlinePlus

Multigroup analysis: TRAIL and DR5 in the plasma from the healthy nonsmokers group, healthy smokers group, COPD nonsmokers group, and COPD smokers group.Notes: (A) TRAIL was highly expressed in the smoking COPD compared with nonsmokers with COPD, healthy smokers, and healthy nonsmokers (P=0.024, P=0.013, and P=0.007, respectively); (B) a similar tendency was in DR5 (P=0.008, P=0.021, and P=0.002, respectively). There was no difference between the healthy nonsmokers and smokers. DR5 was log transformed in the statistical analyses. The levels of TRAIL and DR5 are presented as mean (error bar) and compared by one-way analysis of variance (*P<0.05).Abbreviations: COPD, chronic obstructive pulmonary disease; DR5, decoy receptor 5; NS, nonsmokers; S, smokers; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4644161&req=5

f2-copd-10-2405: Multigroup analysis: TRAIL and DR5 in the plasma from the healthy nonsmokers group, healthy smokers group, COPD nonsmokers group, and COPD smokers group.Notes: (A) TRAIL was highly expressed in the smoking COPD compared with nonsmokers with COPD, healthy smokers, and healthy nonsmokers (P=0.024, P=0.013, and P=0.007, respectively); (B) a similar tendency was in DR5 (P=0.008, P=0.021, and P=0.002, respectively). There was no difference between the healthy nonsmokers and smokers. DR5 was log transformed in the statistical analyses. The levels of TRAIL and DR5 are presented as mean (error bar) and compared by one-way analysis of variance (*P<0.05).Abbreviations: COPD, chronic obstructive pulmonary disease; DR5, decoy receptor 5; NS, nonsmokers; S, smokers; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand.

Mentions: The circulating TRAIL levels in COPD patients were significantly upregulated in comparison with healthy volunteers (50.17±17.70 versus 42.09±15.49 pg/mL, P=0.029, Figure 1A). Similar result was found in DR5 (48.15±22.88 versus 38.94±10.95 pg/mL, P=0.032, Figure 1B). In addition, in multigroup analysis, we found that TRAIL and DR5 expressions were higher in smokers with COPD than those in nonsmokers with COPD (55.68±16.44 versus 45.55±17.65 pg/mL, P=0.024; 55.06±25.26 versus 42.35±19.22 pg/mL, P=0.008, respectively), healthy smokers (41.03±21.00 pg/mL, P=0.013; 39.38±10.64 pg/mL, P=0.021, respectively), and healthy nonsmokers (42.65±12.22 pg/mL, P=0.007; 38.71±11.34 pg/mL, P=0.002, respectively). However, there was no difference observed among the healthy nonsmokers, healthy smokers, and nonsmokers with COPD (Figure 2A and B).


Increased serum TRAIL and DR5 levels correlated with lung function and inflammation in stable COPD patients.

Wu Y, Shen Y, Zhang J, Wan C, Wang T, Xu D, Yang T, Wen F - Int J Chron Obstruct Pulmon Dis (2015)

Multigroup analysis: TRAIL and DR5 in the plasma from the healthy nonsmokers group, healthy smokers group, COPD nonsmokers group, and COPD smokers group.Notes: (A) TRAIL was highly expressed in the smoking COPD compared with nonsmokers with COPD, healthy smokers, and healthy nonsmokers (P=0.024, P=0.013, and P=0.007, respectively); (B) a similar tendency was in DR5 (P=0.008, P=0.021, and P=0.002, respectively). There was no difference between the healthy nonsmokers and smokers. DR5 was log transformed in the statistical analyses. The levels of TRAIL and DR5 are presented as mean (error bar) and compared by one-way analysis of variance (*P<0.05).Abbreviations: COPD, chronic obstructive pulmonary disease; DR5, decoy receptor 5; NS, nonsmokers; S, smokers; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4644161&req=5

f2-copd-10-2405: Multigroup analysis: TRAIL and DR5 in the plasma from the healthy nonsmokers group, healthy smokers group, COPD nonsmokers group, and COPD smokers group.Notes: (A) TRAIL was highly expressed in the smoking COPD compared with nonsmokers with COPD, healthy smokers, and healthy nonsmokers (P=0.024, P=0.013, and P=0.007, respectively); (B) a similar tendency was in DR5 (P=0.008, P=0.021, and P=0.002, respectively). There was no difference between the healthy nonsmokers and smokers. DR5 was log transformed in the statistical analyses. The levels of TRAIL and DR5 are presented as mean (error bar) and compared by one-way analysis of variance (*P<0.05).Abbreviations: COPD, chronic obstructive pulmonary disease; DR5, decoy receptor 5; NS, nonsmokers; S, smokers; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand.
Mentions: The circulating TRAIL levels in COPD patients were significantly upregulated in comparison with healthy volunteers (50.17±17.70 versus 42.09±15.49 pg/mL, P=0.029, Figure 1A). Similar result was found in DR5 (48.15±22.88 versus 38.94±10.95 pg/mL, P=0.032, Figure 1B). In addition, in multigroup analysis, we found that TRAIL and DR5 expressions were higher in smokers with COPD than those in nonsmokers with COPD (55.68±16.44 versus 45.55±17.65 pg/mL, P=0.024; 55.06±25.26 versus 42.35±19.22 pg/mL, P=0.008, respectively), healthy smokers (41.03±21.00 pg/mL, P=0.013; 39.38±10.64 pg/mL, P=0.021, respectively), and healthy nonsmokers (42.65±12.22 pg/mL, P=0.007; 38.71±11.34 pg/mL, P=0.002, respectively). However, there was no difference observed among the healthy nonsmokers, healthy smokers, and nonsmokers with COPD (Figure 2A and B).

Bottom Line: Several studies have suggested that tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its receptors were not only involved in diseases associated with apoptosis but also in inflammatory diseases.Serum levels of TRAIL, decoy receptor 5 (DR5), C-reactive protein, and tumor necrosis factor-α were analyzed using multiplex enzyme-linked immunosorbent assay kits.Mean levels of serum TRAIL and DR5 were significantly higher in COPD patients than those in controls (50.17±17.70 versus 42.09±15.49 pg/mL, P=0.029; 48.15±22.88 versus 38.94±10.95 pg/mL, P=0.032, respectively).

View Article: PubMed Central - PubMed

Affiliation: Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University, Chengdu, Sichuan, People's Republic of China ; Division of Pulmonary Diseases, State Key Laboratory of Biotherapy of China, Chengdu, Sichuan, People's Republic of China.

ABSTRACT

Background: Chronic obstructive pulmonary disease (COPD) is associated with abnormal systemic inflammation, and apoptosis is one of the pathogenic mechanisms of COPD. Several studies have suggested that tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its receptors were not only involved in diseases associated with apoptosis but also in inflammatory diseases. However, limited data about the possible relationship between COPD and TRAIL/TRAIL-receptors are available.

Objective: To evaluate the potential relationship between TRAIL/TRAIL-receptors and COPD.

Methods: Serum levels of TRAIL, decoy receptor 5 (DR5), C-reactive protein, and tumor necrosis factor-α were analyzed using multiplex enzyme-linked immunosorbent assay kits. Then, serum levels of TRAIL and DR5 in 57 COPD patients with 35 healthy controls were compared and correlated with lung function and systemic inflammation.

Results: Mean levels of serum TRAIL and DR5 were significantly higher in COPD patients than those in controls (50.17±17.70 versus 42.09±15.49 pg/mL, P=0.029; 48.15±22.88 versus 38.94±10.95 pg/mL, P=0.032, respectively). Serum levels of TRAIL and DR5 correlated inversely with forced expiratory volume in 1 second % predicted, an index of lung function in COPD (r=-0.354, P=0.007 for TRAIL; r=-0.394, P=0.002 for DR5) in all participants (r=-0.291, P=0.005 for TRAIL; r=-0.315, P=0.002 for DR5), while DR5 correlated positively with C-reactive protein (r=0.240, P=0.021 for total subjects) and TRAIL correlated positively with tumor necrosis factor-α (r=0.371, P=0.005 for COPD; r=0.349, P=0.001 for total subjects).

Conclusion: Our results suggested that circulating TRAIL and DR5 increased in COPD patients and were associated with lung function and systemic inflammation in COPD. Future studies are needed to verify whether and how TRAIL and its receptors play roles in COPD.

No MeSH data available.


Related in: MedlinePlus